LSA
VKTX icon

Leonteq Securities AG’s Viking Therapeutics VKTX Stock Holding History

Leonteq Securities AG’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,000
Closed -$105K – 1526
2025
Q3 		$105K Buy
+4,000
New +$119K ﹤0.01% 736

Other funds holding VKTX

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
IFWM
Institute for Wealth Management Denver, Colorado $1.13B AUM 39.73% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
LA
LBP AM Paris, France $10B AUM 43.88% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Leonteq Securities AG's VKTX Position: Q2 2026 in Review

Leonteq Securities AG reduced its Viking Therapeutics (VKTX) stake by 32% in Q2 2026, selling an estimated $238K and leaving 15,457 shares worth $603K. The position accounts for 0.02% of the portfolio, ranked #363.

Leonteq Securities AG first reported a position in VKTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $742K in Q1 2026. 116 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Leonteq Securities AG held 15,457 shares of Viking Therapeutics worth $603K as of Q2 2026.
  • Leonteq Securities AG sold 7,355 Viking Therapeutics shares in Q2 2026, an estimated $238K.
  • Viking Therapeutics made up 0.02% of Leonteq Securities AG's portfolio in Q2 2026, its #363 holding.
  • Leonteq Securities AG first reported a position in Viking Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Leonteq Securities AG's Viking Therapeutics position peaked at $742K in Q1 2026.
  • 116 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Leonteq Securities AG's 13F filing for Q2 2026, filed 27 Jul 2026.